Barclays PLC Has $186,000 Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH)

Barclays PLC lifted its stake in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) by 317.2% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 40,644 shares of the company’s stock after buying an additional 30,902 shares during the quarter. Barclays PLC owned about 0.08% of scPharmaceuticals worth $186,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in SCPH. Rubric Capital Management LP grew its holdings in shares of scPharmaceuticals by 35.5% during the third quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock valued at $21,774,000 after buying an additional 1,250,000 shares during the last quarter. King Luther Capital Management Corp raised its stake in shares of scPharmaceuticals by 0.9% in the third quarter. King Luther Capital Management Corp now owns 2,225,790 shares of the company’s stock worth $10,150,000 after purchasing an additional 20,650 shares during the last quarter. Suvretta Capital Management LLC bought a new position in shares of scPharmaceuticals in the third quarter valued at approximately $9,343,000. Thrivent Financial for Lutherans boosted its position in shares of scPharmaceuticals by 1.4% during the third quarter. Thrivent Financial for Lutherans now owns 1,048,938 shares of the company’s stock valued at $4,783,000 after buying an additional 14,866 shares during the last quarter. Finally, Stonepine Capital Management LLC grew its holdings in scPharmaceuticals by 84.7% during the third quarter. Stonepine Capital Management LLC now owns 778,874 shares of the company’s stock worth $3,552,000 after buying an additional 357,171 shares in the last quarter. 89.52% of the stock is owned by institutional investors.

scPharmaceuticals Stock Down 1.7 %

Shares of NASDAQ:SCPH opened at $3.56 on Wednesday. The company has a market capitalization of $178.14 million, a PE ratio of -1.87 and a beta of 0.11. scPharmaceuticals Inc. has a 1 year low of $3.08 and a 1 year high of $6.54. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89. The business has a fifty day moving average price of $3.61 and a two-hundred day moving average price of $4.30.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on SCPH shares. Craig Hallum cut their price objective on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of scPharmaceuticals in a research report on Thursday, November 14th.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.